SCHEMBL6902047

SCHEMBL6902047

Cc1ccc(-c2nnc(N)s2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
LMNA P02545 2/20 1.00
KDM4E B2RXH2 10/20 0.66
MGAM O43451 4/20 0.66
GAA P10253 4/20 0.66
SI P14410 4/20 0.66
MGAM2 Q2M2H8 4/20 0.66
NOTUM Q6P988 1/20 0.66
RAB9A P51151 6/20 0.65
NPC1 O15118 4/20 0.65
HSD17B10 Q99714 3/20 0.65
MAPT P10636 3/20 0.65
HPGD P15428 2/20 0.65
TP53 P04637 2/20 0.65
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
CSNK2A2 P19784 1/20 0.58
CSNK2B P67870 1/20 0.58
CSNK2A1 P68400 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10000252 0.84 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL28851907 0.83 KDM4E (0.70) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL10163324 0.80 KDM4E (0.68) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL23918236 0.79 KDM4E (0.66) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL11340093 0.79 MGAM (1.00) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL474273 0.79 KDM4E (0.66) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL1143313 0.79 KDM4E (0.66) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL6538646 0.79 KDM4E (0.66) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL1143676 0.79 KDM4E (1.00) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM
SCHEMBL17725821 0.79 KDM4E (0.66) ALDH1A1SMN1; SMN2LMNAKDM4EMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101284820-B Amino peptidase inhibiting substance and synthetic method UNIV NANCHANG 2011-05-04 CN claimed
CN-101284820-A Amino peptidase inhibiting substance and synthetic method UNIV NANCHANG (CN) 2008-10-15 CN claimed
CN-119661470-A Thiadiazole urea compound or pharmaceutically acceptable salt thereof, pharmaceutical composition and application thereof 安徽医科大学 2025-03-21 CN disclosed
US-12187729-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-01-07 US disclosed
EP-3892622-B1 COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF KOREA RES INST CHEMICAL TECH (KR) 2024-07-24 EP disclosed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 US disclosed
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-12-12 US disclosed
CN-113166159-B Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof 韩国化学研究院 2023-10-24 CN disclosed
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
CN-112279845-B Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof 中国医学科学院药物研究所 2023-07-28 CN disclosed
US-7867980-B2 Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-11 US disclosed
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD 2010-07-22 US disclosed
CN-101284820-A Amino peptidase inhibiting substance and synthetic method UNIV NANCHANG (CN) 2008-10-15 CN disclosed
EP-0159707-B1 TRIAZOLOPYRIMIDINE DERIVATIVES DAIICHI SEIYAKU CO., LTD. (JP) 1990-01-24 EP disclosed
US-4652646-A ANTIALLERGENS DAIICHI SEIYAKU CO., LTD. (JP) 1987-03-24 US disclosed
EP-0159707-A2 Triazolopyrimidine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1985-10-30 EP disclosed
EP-0005783-B1 IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS BAYER AG (DE) 1981-12-30 EP disclosed
US-4265898-A ANTICOAGULANTS BAYER AKTIENGESELLSCHAFT (DE) 1981-05-05 US disclosed
EP-0005783-A1 Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments BAYER AG (DE) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187729-B2 Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof PDE9A, PDE5A, PDE3A ALDH1A1 517/4885SMN1; SMN2 944/4885LMNA 1466/4885
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 ALDH1A1 575/4885SMN1; SMN2 4692/4885LMNA 4359/4885
US-11839613-B2 Pyrimidine derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 ALDH1A1 468/4885SMN1; SMN2 4606/4885LMNA 4601/4885
US-20100184746-A1 LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT SIRT6, LAS1L, MRPS18A ALDH1A1 3217/4885SMN1; SMN2 1070/4885LMNA 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.